Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 5/20 | 0.40 |
| ▸ | CES1 | P23141 | 5/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804201 | 0.89 | P2RX4 (0.47) | P2RX4KMT2AALOX5ALDH1A1IDO1 | |
| SCHEMBL15470876 | 0.87 | TSHR (0.46) | TSHRCES2CES1MAPTMEN1 | |
| SCHEMBL15470893 | 0.83 | MAPT (0.47) | TSHRCES2CES1CYP3A4CYP1A2 | |
| SCHEMBL15470902 | 0.81 | TSHR (0.40) | TSHRCES2CES1MAPTHPGD | |
| SCHEMBL15470927 | 0.79 | GPR3 (0.42) | TSHRCES2CES1MEN1KMT2A | |
| SCHEMBL15470921 | 0.78 | TSHR (0.38) | TSHRCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL42428 | 0.76 | TSHR (0.60) | TSHRCES2CES1CYP3A4MAPT | |
| Benzene SCHEMBL28195988 | 0.76 | TSHR (0.60) | TSHRCES2CES1CYP3A4MAPT | |
| SCHEMBL21908165 | 0.76 | P2RX4 (0.45) | P2RX4MAPTMEN1KMT2AALOX5 | |
| SCHEMBL15470937 | 0.74 | IDO1 (0.41) | TSHRCYP3A4CYP1A2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926289-B2 | Compositions, apparatus, systems, and methods for resolving electronic excited states | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2018-03-27 | — | — | US | disclosed |
| US-9765051-B2 | Compositions, apparatus, systems, and methods for resolving electronic excited states | HALLSTAR INNOVATIONS CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9650356-B2 | — | — | 2017-05-16 | — | — | US | disclosed |
| US-9611246-B2 | Compositions, apparatus, systems, and methods for resolving electronic excited states | HALLSTAR INNOVATIONS CORP. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160024046-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2016-01-28 | — | — | US | disclosed |
| US-20160022555-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2016-01-28 | — | — | US | disclosed |
| US-20160002200-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2016-01-07 | — | — | US | disclosed |
| US-9145383-B2 | Compositions, apparatus, systems, and methods for resolving electronic excited states | HALLSTAR INNOVATIONS CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140044654-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | HALLSTAR INNOVATIONS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024046-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | RECQL, BLM, WRN | TSHR 4095/4885CES2 1265/4885CES1 2679/4885 |
| US-20160002200-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | RECQL, BLM, WRN | TSHR 4095/4885CES2 1265/4885CES1 2679/4885 |
| US-20140044654-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | RECQL, BLM, WRN | TSHR 4095/4885CES2 1265/4885CES1 2679/4885 |
| US-20160022555-A1 | COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES | RECQL, BLM, WRN | TSHR 4095/4885CES2 1265/4885CES1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.